4
Changes in Ownership
Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000002
Chief Operating Officer sold 13,000 shares at an average $28.52 ($370,795)
- Chief Operating Officer acquired 5,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Sandler Laura Lee Chief Operating Officer | 2026-01-02 | Option exercise 10b5-1 | +5,000 | $7.80 | $39,000 | 218,084 | D |
| Sandler Laura Lee Chief Operating Officer | 2026-01-02 | Sale 10b5-1 | −8,748 | $28.17 | $246,396 | 209,336 | D |
| Sandler Laura Lee Chief Operating Officer | 2026-01-02 | Sale 10b5-1 | −3,144 | $29.08 | $91,432 | 206,192 | D |
| Sandler Laura Lee Chief Operating Officer | 2026-01-02 | Sale 10b5-1 | −1,108 | $29.75 | $32,967 | 205,084 | D |
| Derivatives | |||||||
| Sandler Laura Lee Chief Operating Officer | 2026-01-02 | Option exercise · Employee Warrant (right to buy) 10b5-1 | −5,000 | 94,996 | D | ||
| Open-market sales · 13,000 sh · avg $28.52 · $370,795 | |||||||
Loading xslF345X05/form4.xml…